Overview

The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries

Status:
Unknown status
Trial end date:
2010-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy of rebamipide for NSAID-induced small-intestinal injuries.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nagoya University
Treatments:
Anti-Inflammatory Agents, Non-Steroidal
Rebamipide
Criteria
Inclusion Criteria:

- Written informed consent

- 20 to 85 years of age

- RA, OA, or low back pain

- No change of drugs before 3 months

- Under 5 mg of corticosteroid use

- CRP < 1mg/dl

- Small-intestinal mucosal injuries more than one

- Hemoglobin level is below normal range

Exclusion Criteria:

- Known or suspected small-bowel disease, including Crohn's disease and seronegative
arthritis

- Prostaglandins, metronidazole or salazosulfapyridine

- Can not swallow

- Eith pacemaker

- After gastrointestinal operation

- Serious concomitant cardiovascular, endocrine, gastrointestinal(including symptoms of
ileus), neurologic, psychiatric, renal, or respiratory disease.

- Taking rebamipide before one week

- Any other conditions that the investigator feels would interfere with data
interpretation or create under risk.